Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| IGE-M52H3 | Mouse | Mouse IgE Fc Protein, His Tag (MALS & SPR verified) |  |
|
|
| IGE-C52H3 | Cynomolgus | Cynomolgus IgE Fc Protein, His Tag (MALS & SPR verified) |  |
|
|
| IGE-H52H9 | Human | Human IgE Fc Protein, His Tag |  |
|
Human Fc epsilon RI alpha, His Tag (Cat. No. FCA-H5228) immobilized on CM5 Chip can bind Mouse IgE Fc Protein, His Tag (Cat. No. IGE-M52H3) with an affinity constant of 0.391 nM as determined in a SPR assay (Biacore 8K) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Omalizumab biosimilar (IBC Generium) | GNR-044 | Approved | Ibc Generium | Genolair | Russian Federation | Chronic Urticaria; Asthma | Generium Pharmaceuticals | 2022-02-09 | Chronic Urticaria; Asthma | Details |
| Omalizumab biosimilar (Mabtech) | STI-004; CMAB007; CMAB-007 | Approved | Taizhou Maibo Taike Biotechnology Co Ltd | 奥迈舒 | Mainland China | Asthma | Taizhou Mabtech Pharmaceutical Co Ltd | 2023-05-19 | Chronic Urticaria; Allergic asthma; Asthma | Details |
| Omalizumab | GN-1560; RG-3648; IGE-025A; rhuMAb-E25; R-3648; E-25; IGE-025 | Approved | Novartis Pharma Ag, Genentech Inc | Xolair, 茁乐 | Australia | Asthma; Chronic Urticaria | null | 2002-01-01 | Pulmonary Disease, Chronic Obstructive; Job Syndrome; Asthma; Sinusitis; Urticaria; Esophagitis; Pemphigoid, Bullous; Bronchitis; Peanut Hypersensitivity; Allergic asthma; Infertility, Female; Angioedema; Dermatitis, Atopic; Mastocytosis; Hypersensitivity; Rhinitis; Gastroenteritis; Respiratory Tract Infections; Eosinophilic Esophagitis; Lupus Erythematosus, Systemic; Food Hypersensitivity; Immune System Diseases; Nose Diseases; Coronavirus Disease 2019 (COVID-19); Milk Hypersensitivity; Colonic Neoplasms; Sjogren's Syndrome; Nasal Polyps; Chronic Urticaria; Autism Spectrum Disorder; Rhinitis, Allergic, Seasonal; Anaphylaxis; Drug Hypersensitivity | Details |
| Omalizumab biosimilar (IBC Generium) | GNR-044 | Approved | Ibc Generium | Genolair | Russian Federation | Chronic Urticaria; Asthma | Generium Pharmaceuticals | 2022-02-09 | Chronic Urticaria; Asthma | Details |
| Omalizumab biosimilar (Mabtech) | STI-004; CMAB007; CMAB-007 | Approved | Taizhou Maibo Taike Biotechnology Co Ltd | 奥迈舒 | Mainland China | Asthma | Taizhou Mabtech Pharmaceutical Co Ltd | 2023-05-19 | Chronic Urticaria; Allergic asthma; Asthma | Details |
| Omalizumab | GN-1560; RG-3648; IGE-025A; rhuMAb-E25; R-3648; E-25; IGE-025 | Approved | Novartis Pharma Ag, Genentech Inc | Xolair, 茁乐 | Australia | Asthma; Chronic Urticaria | null | 2002-01-01 | Pulmonary Disease, Chronic Obstructive; Job Syndrome; Asthma; Sinusitis; Urticaria; Esophagitis; Pemphigoid, Bullous; Bronchitis; Peanut Hypersensitivity; Allergic asthma; Infertility, Female; Angioedema; Dermatitis, Atopic; Mastocytosis; Hypersensitivity; Rhinitis; Gastroenteritis; Respiratory Tract Infections; Eosinophilic Esophagitis; Lupus Erythematosus, Systemic; Food Hypersensitivity; Immune System Diseases; Nose Diseases; Coronavirus Disease 2019 (COVID-19); Milk Hypersensitivity; Colonic Neoplasms; Sjogren's Syndrome; Nasal Polyps; Chronic Urticaria; Autism Spectrum Disorder; Rhinitis, Allergic, Seasonal; Anaphylaxis; Drug Hypersensitivity | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Omalizumab biosimilar (Synermore Biologics) | SYN-008 | Phase 3 Clinical | Cspc Baike (Shandong) Biopharmaceutical Co Ltd, Synermore Biologics (Suzhou) Co Ltd | Chronic Urticaria | Details |
| Omalizumab biosimilar (Reliance Life Sciences) | R-TPR-022 | Phase 3 Clinical | Reliance Life Sciences | Asthma | Details |
| Omalizumab biosimilar (Teva) | TEV-45779 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Chronic Urticaria | Details |
| Ligelizumab | QGE-031 | Phase 3 Clinical | Genentech Inc | Chronic Urticaria; Food Hypersensitivity; Pemphigoid, Bullous; Asthma; Urticaria; Peanut Hypersensitivity; Dermatitis, Atopic; Hypersensitivity | Details |
| Omalizumab biosimilar (BiosanaPharma) | ADL-018; AVT-23; BP-001 | Phase 3 Clinical | BiosanaPharma BV | Chronic Urticaria; Allergic asthma | Details |
| Recombinant anti-IgE monoclonal antibody(Cspc Baike) | Phase 3 Clinical | Cspc Baike (Shandong) Biopharmaceutical Co Ltd | Chronic Urticaria; Asthma | Details | |
| Omalizumab biosimilar (Yuanda Shuyang) | SYB-507 | Phase 3 Clinical | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | Chronic Urticaria; Allergic asthma; Asthma | Details |
| Anti-CEmX monoclonal antibody (Fountain Biopharma) | h4B12; FB-825 | Phase 2 Clinical | Academia Sinica | Asthma; Dermatitis, Atopic | Details |
| UB-221 | UB-221 | Phase 2 Clinical | Chinese Academy Of Sciences | Chronic Urticaria | Details |
| Omalizumab biosimilar (Glenmark) | GBR-310 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Chronic Urticaria; Asthma | Details |
| Bifidobacterium Bifidum（Sun Yat-sen University） | Phase 2 Clinical | Sun Yat-Sen University | Carcinoma, Hepatocellular | Details | |
| LP-003 (Tianchen Biomedical) | LP-003 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Rhinitis, Allergic, Seasonal; Chronic Urticaria; Nasal Polyps; Rhinitis, Allergic; Allergic asthma; Asthma; Sinusitis | Details |
| ADP-101 | ADP-101 | Phase 2 Clinical | Alladapt Immunotherapeutics Inc | Food Hypersensitivity | Details |
| Omalizumab biosimilar (Fountain BioPharma) | FB-317 | Phase 1 Clinical | Academia Sinica | Asthma; Urticaria | Details |
| Omalizumab biosimilar（Yuhan） | YH-35324 | Phase 1 Clinical | Yuhan Corp | Chronic Urticaria; Immune System Diseases; Urticaria; Hypersensitivity | Details |
| IGNX-001 | IGNX-001; IGNX001; IGX-0107 and IGX-0109 | Phase 1 Clinical | IgGenix Inc | Peanut Hypersensitivity | Details |
| JYB-1904 | JYB-1904 | Phase 1 Clinical | Jiangsu Jiye Biopharmaceutical Co Ltd | Allergic asthma; Urticaria; Asthma | Details |
| Omalizumab biosimilar (Tianchen Biomedical) | Phase 1 Clinical | Longbio Pharma (Suzhou) Co Ltd | Chronic Urticaria | Details | |
| Anti-IgE allergy vaccine (United Biomedical) | Phase 1 Clinical | United Biomedical Inc | Hypersensitivity | Details | |
| Omalizumab biosimilar (Synermore Biologics) | SYN-008 | Phase 3 Clinical | Cspc Baike (Shandong) Biopharmaceutical Co Ltd, Synermore Biologics (Suzhou) Co Ltd | Chronic Urticaria | Details |
| Omalizumab biosimilar (Reliance Life Sciences) | R-TPR-022 | Phase 3 Clinical | Reliance Life Sciences | Asthma | Details |
| Omalizumab biosimilar (Teva) | TEV-45779 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Chronic Urticaria | Details |
| Ligelizumab | QGE-031 | Phase 3 Clinical | Genentech Inc | Chronic Urticaria; Food Hypersensitivity; Pemphigoid, Bullous; Asthma; Urticaria; Peanut Hypersensitivity; Dermatitis, Atopic; Hypersensitivity | Details |
| Omalizumab biosimilar (BiosanaPharma) | ADL-018; AVT-23; BP-001 | Phase 3 Clinical | BiosanaPharma BV | Chronic Urticaria; Allergic asthma | Details |
| Recombinant anti-IgE monoclonal antibody(Cspc Baike) | Phase 3 Clinical | Cspc Baike (Shandong) Biopharmaceutical Co Ltd | Chronic Urticaria; Asthma | Details | |
| Omalizumab biosimilar (Yuanda Shuyang) | SYB-507 | Phase 3 Clinical | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | Chronic Urticaria; Allergic asthma; Asthma | Details |
| Anti-CEmX monoclonal antibody (Fountain Biopharma) | h4B12; FB-825 | Phase 2 Clinical | Academia Sinica | Asthma; Dermatitis, Atopic | Details |
| UB-221 | UB-221 | Phase 2 Clinical | Chinese Academy Of Sciences | Chronic Urticaria | Details |
| Omalizumab biosimilar (Glenmark) | GBR-310 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Chronic Urticaria; Asthma | Details |
| Bifidobacterium Bifidum（Sun Yat-sen University） | Phase 2 Clinical | Sun Yat-Sen University | Carcinoma, Hepatocellular | Details | |
| LP-003 (Tianchen Biomedical) | LP-003 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Rhinitis, Allergic, Seasonal; Chronic Urticaria; Nasal Polyps; Rhinitis, Allergic; Allergic asthma; Asthma; Sinusitis | Details |
| ADP-101 | ADP-101 | Phase 2 Clinical | Alladapt Immunotherapeutics Inc | Food Hypersensitivity | Details |
| Omalizumab biosimilar (Fountain BioPharma) | FB-317 | Phase 1 Clinical | Academia Sinica | Asthma; Urticaria | Details |
| Omalizumab biosimilar（Yuhan） | YH-35324 | Phase 1 Clinical | Yuhan Corp | Chronic Urticaria; Immune System Diseases; Urticaria; Hypersensitivity | Details |
| IGNX-001 | IGNX-001; IGNX001; IGX-0107 and IGX-0109 | Phase 1 Clinical | IgGenix Inc | Peanut Hypersensitivity | Details |
| JYB-1904 | JYB-1904 | Phase 1 Clinical | Jiangsu Jiye Biopharmaceutical Co Ltd | Allergic asthma; Urticaria; Asthma | Details |
| Omalizumab biosimilar (Tianchen Biomedical) | Phase 1 Clinical | Longbio Pharma (Suzhou) Co Ltd | Chronic Urticaria | Details | |
| Anti-IgE allergy vaccine (United Biomedical) | Phase 1 Clinical | United Biomedical Inc | Hypersensitivity | Details |
This web search service is supported by Google Inc.
A-Z
